CN1899389B - Medicinal composition for preventing and treating female senile diseases and method for preparing said preparation - Google Patents
Medicinal composition for preventing and treating female senile diseases and method for preparing said preparation Download PDFInfo
- Publication number
- CN1899389B CN1899389B CN200610011056A CN200610011056A CN1899389B CN 1899389 B CN1899389 B CN 1899389B CN 200610011056 A CN200610011056 A CN 200610011056A CN 200610011056 A CN200610011056 A CN 200610011056A CN 1899389 B CN1899389 B CN 1899389B
- Authority
- CN
- China
- Prior art keywords
- preparation
- isoflavone
- acid
- treat
- prevent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of medicinal composition for preventing and treating female senile diseases and its preparation process. The medicinal composition consists of isoflavone, panoxadiol type saponin, cimicifuga rhizome extract and calendic acid. It has high stability, and can replenish female with paraestrogen to prevent diseases caused by estrogen decrease, improve senility symptoms, nurse skin, resist oxidation and eliminate the accumulation of free radical and other toxic matters.
Description
Affiliated technical field
The present invention relates to the prescription of a kind of prevention and treatment female aging disease, be used for prevention or the various senile diseases of treatment women (as acceptable preparations such as the soft capsule of diseases such as osteoporosis, premenstrual syndrome, skin aging, cardiovascular and cerebrovascular vessel are aging, liquid capsule, liquid agent and preparation method thereof thereby can prepare.
Background technology
About women to 18 year old, reach maturity, subsequently with advancing age, intravital self estrogen secretion begins gradually few gradually, thereby makes women's skin, physiology ripe gradually and begin move towards aging.When entering menopause to about 40 years old, estrogen secretion obviously reduces, and causes some organic pathological changes, is hypo-ovaria, osteoporosis, cutis laxa, anxious state of mind etc. significantly.Reduce for solving female estrogen, what people expected at first naturally is complementing estrogen, but through finding that though complementing estrogen can solve the problem that estrogen decrease produces after the clinical practice of decades, but but the other problem that causes hormone to bring, as cancer etc.Therefore, seek the class estrogen substance and become an important direction.The effective ingredients in plant of flavonoid class has become medical science man's target.Isoflavone (isoflavonoid) is a big class material, and isolation identification goes out more than 600 kind of isoflavone from plant.Wherein the isoflavone compounds in Semen sojae atricolor source is comparatively common.The functional study of isoflavone and clinical efficacy, the physiological function that relates to is more, has affirmed fully the estrogen-like effects, anti-oxidation function, antitumor action, vascular protection effect of isoflavone, to the effect of bone metabolism.A large amount of research and the clinical isoflavone that confirmed can protect against osteoporosis, alleviate the uncomfortable disease of Woman climacteric and reduce evidence of coronary heart diseases.Drugs approved by FDA soybean isoflavone functional food enters American market, and soybean isoflavone formed industry rapidly in the U.S. in after this several years, in existing more than the 300 kind of Related product of the U.S., nearly 2,000,000,000 dollars of annual sales amount.In countries and regions such as Europe, Japan, Korea S, also become a kind of novel health food.Since nineteen ninety-six, by 2004, the health food that contains soybean isoflavone of Chinese approved had 35 products, the function that these products are declared mainly concentrate on slow down aging, the beauty treatment above.Chinese soybean, Radix Puerariae resource are very abundant, and research and development osajin product has very remarkable social benefit and economic benefit.Therefore isoflavone is applied in the health food, a lot of abroad, mainly be to be used for slow down aging, cardiovascular and cerebrovascular disease, osteoporosis etc.But compare with American-European countries, the isoflavone level in Asia (particularly south east asia) crowd's urine or the blood is much higher, and the sickness rate and the order of severity of relevant with the estrogen reduction simultaneously disease all will be hanged down.But women's comprehensive body constitution and old and feeble not reduction.
Summary of the invention
The objective of the invention is at isoflavone content in the body still high, but occur still that body constitution descends, old and feeble significantly women crowd provides a kind of preparation method that is used to prevent and treat the pharmaceutical composition and the preparation thereof of female aging disease.
The object of the present invention is achieved like this:
The pharmaceutical composition that is used to prevent and treats the female aging disease is formed functional component and is formed jointly by isoflavone, panoxadiol's type saponin, Rhizoma Cimicifugae extract, jeceric acid, and each functional component proportion of composing is in its prescription:
Isoflavone 1.5%～30%
Panoxadiol's type saponin 1.5%～22.1%
Rhizoma Cimicifugae extract 1.2%～17.9%
Jeceric acid 30%～95.8%.
Wherein each active substance is respectively isoflavone: soybean isoflavone, Radix Puerariae isoflavone class plant isoflavone; Panoxadiol's type saponin is the diol type dammarane type saponin that is derived from panax species, as contains Radix Ginseng or the isolating effective site product of arasaponin that Rb1 is a main component, also can be saponin of Radix Notoginseng leaf or Radix Panacis Quinquefolii saponin; Rhizoma Cimicifugae extract is meant that what extracted by Rhizoma Cimicifugae is the extract of main active to contain triterpene saponin (2～20%); Jeceric acid is meant trienic acid such as gamma-Linolenic acid, alpha-linolenic acid and the Pinolenic acid that contains 18 carbon atoms.
Isoflavone-containing 5～100mg, panoxadiol's type saponin 5～74mg, Rhizoma Cimicifugae extract 4～60mg, jeceric acid 100～321mg in the each dosage that uses of the finished product of making.
The agent substrate of soft capsule is one or more compositions in plant edible foods such as lists such as oleic acid, linoleic acid and/or polyunsaturated fatty acid or the medicinal oil.
Deodorant tune can be added as required in the medicinal liquid, as Oleum Cinnamomi.
Product can be made acceptable preparations such as soft capsule, liquid capsule, liquid agent.
Research solves the problem of female aging and body constitution decline with the Traditional Chinese medical theory compound recipe.Aging is a kind of yang-energy decline, the interior poisonous substance of body is constantly accumulated simultaneously, and human body is produced the process of toxic action.Find that after deliberation Ranunculaceae Rattleroot plant Rhizoma Cimicifugae Cimicifuga foetida L. has good elevate a turnable ladder yang-energy, heat-clearing toxin-expelling functions, can well be at the cause of disease and the disease of aging, solve that the body constitution that the age increases in women year and occur descends, the problem of poison accumulation.Panoxadiol's type material then can fundamentally stimulate bone marrow to produce erythrocyte, solves anemia problem and anxious state of mind problem that the women extensively exists.The jeceric acid ester has good alimentary health-care function, makes the especially essential nutrient substance of women of human body, is commonly called as vitaminF.Gamma-Linolenic acid wherein (γ-Linolenic acid or Gamma-Linolenic acid are called for short GLA), it is the fatty acid of needed by human, it also is the synthetic precursor of human body to the significant prostaglandin of life, body disease-resistant anti-aging there is significant good effect, mainly as premenstrual syndrome, erythra, antiinflammatory, cardiovascular and cerebrovascular disease, anticancer etc.Alpha-linolenic acid α-Linolenic acid is the fatty acid of needed by human.Pinolenic acid Pinolenic acid has preferably effect for reducing blood fat, keep moisture of skin, whiten and discharge effect such as the happy factor.Women's body constitution descends and aging is closely-related two kinds of presentations, reason is that poison accumulation increases in the bodies such as estrogen secretion deficiency, free radical, the degradation combined cause brings out under anemia and the yang-energy, solution can only be " synthtic price index comprehensively solves ", promptly uses the compound recipe theory the most effective.Drug regimen composition formula of the present invention selects the deficiency of the direct complementing estrogen of isoflavone, and panoxadiol's type saponin is at the anemia problem, and Rhizoma Cimicifugae extract promotes yang-energy, heat-clearing and toxic substances removing, the essential material of jeceric acid ester extra-nutrition, control skin aging.
Drug effect of the present invention: made various product stabilities are good; Product can replenish women's class estrogen, and then the serial disease cause because of estrogen descends of prevention; Improve senile symptom, obviously maintenance skin; Poison accumulations such as antioxidation, removing interior free yl.
The specific embodiment
Embodiment 1, compound recipe isoflavone soft capsule
Prescription (1000):
Soybean isoflavone 5g
Radix Notoginseng panoxadiol type saponin (contains Rb
155%) 5g
Rhizoma Cimicifugae extract 20g
Alpha-linolenic acid 160g
Gamma-Linolenic acid 60g
Linoleic acid 160g
Oleic acid 40g
Red pigment is an amount of.
Preparation technology: under nitrogen protection, liquid oiliness things such as the alpha-linolenic acid of formula ratio and gamma-Linolenic acid are mixed, add soybean isoflavone and Radix Notoginseng panoxadiol type saponin, Rhizoma Cimicifugae extract, fully stir, dissolving, filter, the degassing, deliver in the jar of filling machine top, stand-by; Be ready to the gelatin solution that the rubber in the soft capsule filling machine top insulation gelatin jar is used simultaneously, stand-by; Under 300,000 grades, 21 ℃～25 ℃, the condition of RH%:39～41%, start rotating mould press pelleting, the soft capsule of making is cleaned, [28 ± 2] ℃ dry 19-27 hour down, packing, packing promptly gets 1000 of the red soft capsule finished products of compound recipe isoflavone soft capsule 450mg (intragranular is tolerant heavy).
Embodiment 2, compound recipe isoflavone soft capsule
Prescription (1000):
Radix Puerariae isoflavone 45g
Saponin of Radix Notoginseng leaf 25g
Rhizoma Cimicifugae extract 38g
Alpha-linolenic acid 154g
Gamma-Linolenic acid 140g
Linoleic acid 60g
Oleic acid 50g
Gelatin is an amount of
Glycerol is an amount of
Amaranth is an amount of
Brilliant black is an amount of.
Preparation technology: with embodiment 1 (summary).1000 of the aubergine soft capsule finished products of 512mg content.
Embodiment 3, compound recipe isoflavone soft capsule
Prescription (1000):
Radix Puerariae isoflavone 100g
Radix Panacis Quinquefolii saponin 5g
Rhizoma Cimicifugae extract 12g
Alpha-linolenic acid 200g
Gamma-Linolenic acid 10g
Linoleic acid 100g
Oleic acid 100g
Gelatin is an amount of
Glycerol is an amount of
Edible titanium dioxide is an amount of.
Preparation technology: with embodiment 1 (summary).1000 of every white soft capsule finished products that contains the 519mg content.
Embodiment 4: compound recipe isoflavone liquid capsule
Prescription (1000):
Radix Puerariae isoflavone 8g
Panoxadiol's type saponin (contains Rb
180%) 10g
Rhizoma Cimicifugae extract 6g
Alpha-linolenic acid 50g
Gamma-Linolenic acid 50g
Linoleic acid 60g
Oleic acid 49g.
Preparation technology: under nitrogen protection, liquid oiliness things such as the alpha-linolenic acid of formula ratio and gamma-Linolenic acid are mixed, add Radix Puerariae isoflavone and panoxadiol's type saponin, Rhizoma Cimicifugae extract, fully stir, dissolving, filter, the degassing, deliver in the jar of capsule machine top, stand-by; Be ready to green liquid capsule simultaneously,, promptly get green compound recipe isoflavone liquid capsule with the packing of liquid capsule machine.
Embodiment 5: compound recipe isoflavone fat emulsion oral liquid
Prescription (1000)
Soybean isoflavone 10g
Radix Notoginseng panoxadiol type saponin (contains Rb
195%) 9g
Rhizoma Cimicifugae extract (containing triterpene 20%) 48g
Gamma-Linolenic acid 40g
Pinolenic acid 160g
Linoleic acid 60g
Oleic acid 9g
Glycerol 210g
Soybean phospholipid 100g.
Preparation technology: under 100 grades condition, under nitrogen protection, soybean phospholipid is added no saline 5000ml; add fluid, isoflavone, panoxadiol's type saponin, Rhizoma Cimicifugae extracts such as acid and gamma-linolenic again; be stirred to evenly, add glycerol, add no saline to 10000ml.In 70～80 ℃ with organizing beating crusher to make thick breast.Thick breast is cooled to rapidly below 20 ℃, and the high pressure dispersing emulsification machine emulsifying of two step of reuse promptly gets finely divided submicron emulsion (fat milk).Send into racking machine, by every bottle of 10ml packing, Zha Gai, packing, check, qualified, finished product.Can make the compound recipe isoflavone fat emulsion oral liquid finished product of the specification of 1000 10ml.
For of the present invention may the combination clearly is described, above embodiment is provided, but never is in order to limit the present invention, and scope of the present invention is not subjected to the limitation of illustrated embodiment.
Product study of pharmacy and effect:
One, the stability of product
The lucifuge keeping at room temperature of 1,2,3,4,5 five samples of embodiment was placed 1,2,3,6,12 month, checked that on time it is constant substantially that every sample gets outward appearance, and effective ingredient does not change through check yet.Peroxide value is constant.Assay is measured the isoflavone method with ultraviolet method and is measured.Therefore, think that tentatively various products and various prescription all can reach the shelf-life about 1 year.
The stability test result:
The result shows the sample of this invention preparation, and through the preliminarily stabilised investigation, product quality is basicly stable, can reach more than 1 year.
1, product can replenish women's class estrogen, and then the serial disease cause because of estrogen descends of prevention
(1) bone density improving function
Test according to Ministry of Health of the People's Republic of China's middle bone density improving functional check method of version " health food check and assessment technique standard " in 2003.
The prepared sample emulsion of experimental drug: embodiment 5 prescriptions.Gastric infusion is by 25,50, the 100mg/kg.W administration.The result is as follows:
Each treated animal body weight gain situation is: middle dosage group is best, and model group is the poorest.Low dose group also is better than matched group.
Each organizes the retention of femur calcium: high dose group is best, and model group is the poorest.Low dose group also is better than matched group.
Each measurement result of organizing serum calcium is: high dose group is best, and model group is the poorest.Low dose group also is better than matched group.
Compbined test draws, and the compound recipe isoflavone has remarkable promotion animal weightening finish, raising calcium apparent digestibility, the retention of increase femur calcium both to improve effects such as serum calcium cancentration, and every index all is better than calcium carbonate control group.
(2) improve climacteric syndrome
Age, voluntary accepting embodiment 2 samples with each 1 sooner or later of every day, were taken 60 days continuously, observed 180 days, improved the clinical trial of climacteric syndrome 35 of 42～55 years old the volunteers who enters into the climacteric period.Several cardinal symptoms show as following table in the climacteric syndrome as a result:
The result shows that compound recipe isoflavone product improves significantly to the cardinal symptom of climacteric syndrome.
Two, effects such as defying age, antioxidation, removing interior free yl
(1) blood fat reducing
Material
1. animal: SD rat, body weight 180-230g, the quality certification number " the moving pipe of cloud B04 ".
2. medicine and reagent:
The sample code name FYH that compound recipe isoflavone soft capsule embodiment 1 makes
Cholesterol: Shanghai chemical reagent packing, lot number: 050517
Cholate: east, Suzhou medical biochemical product factory produces lot number: 050101
The propylthiouracil sheet: bridge pharmaceutical factory in Guangzhou produces, lot number: 900523
Adeps Sus domestica: commercially available
Fenofibrate: Taixing, Jiangsu pharmaceutical factory produces, lot number: 050816
3. instrument: Mooarch1000 type full automatic biochemical apparatus (U.S.'s product)
Method
1. high fat emulsifying agent preparation
With cholesterol, propylthiouracil sheet pulverize.Be mixed with lipomul (W/V) by 10% cholesterol, 2% cholate, 1% propylthiouracil, 20% Adeps Sus domestica amount with distilled water.Refrigerator is preserved, and the time spent places in the hot bath and melts.
2. the compound recipe isoflavone soft capsule is to the influence of rat hyperlipidemia model serum lipids
With 40 of above-mentioned SD rats, be divided into the heavy dose of group of (1) normal control group (2) model control group (3) FYH small dose group (4) FYH at random, every group of 10 rats, male and female half and half.Grouping back animal every morning (1) group ig give distilled water, and (2) (3) (4) group ig give isopyknic high lipoprotein emulsion; Hereinafter ig145mg/kg, 290mg/kg are respectively organized in (3) (4), and (1) (2) group is given distilled water, continuously 20d.After the last administration, animal fasting 16h, rat eye socket venous plexus is got blood, and separation of serum is with enzymatic assays serum cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL-C), low density lipoprotein, LDL (LDL-C), ApoA (APOA), apolipoprotein B (APOB).
The results are shown in Table.
FLQ
| Group | TC (mmll/L) | TG (mmll/L) | HDL-C (mmll/L) | LDL-C (mmll/L) | APOA (mmll/L) | APOB (mmll/L) |
| The normal control group | 1.37±1.02 | 0.92±0.29 | 0.99±0.25 | 0.18±0.18 | 0.379±0.010 | 0.052±0.042 |
| Model control group | 2.67±0.33 | 0.85±0.22 | 1.12±0.38 | 1.10±0.19 | 0.373±0.011 | 0.050±0.012 |
| Fenofibrate | 2.62±0.25 | 0.74±0.13 | 1.14±0.21 | 1.30±0.31 | 0.384±0.016 | 0.049±0.017 |
| Model+high dose group | 2.30±0.26 * | 0.51±0.23 ** | 1.09±0.23 | 0.92±0.29 | 0.381±0.018 | 0.057±0.005 |
| Group | TC (mmll/L) | TG (mmll/L) | HDL-C (mmll/L) | LDL-C (mmll/L) | APOA (mmll/L) | APOB (mmll/L) |
| Model+low dose group | 2.45±0.28 | 0.54±0.20 ** | 1.04±0.29 | 1.23±0.22 | 0.363±0.005 | 0.051±0.005 |
Model control group and normal control group compare: △ P＜0.05 △ △ P＜0.01
Administration group and model group matched group compare: * P＜0.05**P＜0.01
The result
By table as seen, the FYH high dose group can significantly reduce the TC (P＜0.05) in the hyperlipidemia model rat serum, and low agent group also has reduction trend; Two groups of TG are reduced significantly (P＜0.01); HDL-C, LDL-C, APOA, APOB are not made significant difference.
(2) FYH is to the nootropic effect research of aged animal model
1 material
1.1 laboratory animal ICR mice, body weight 20 ± 2g, male and female half and half are provided by Yunnan Province natural drug pharmacology key lab, and the animal quality certification is numbered: No. the 00205th, the real moving card in Yunnan.
1.1.2 medicine and reagent
1.1.2.1 the sample that test sample embodiment 2 makes (code name FYH).Face the time spent, be mixed with 5%, 10% and 20% suspension with 1% carmethose.
1.1.2.2 reference substance brain recovering capsule faces the time spent, the carboxylic first fiber sodium with 1% is mixed with 5% suspension.
1.2 experimental technique and result
Earlier mice is divided into blank group and aging model group.Aging model group mice retrobulbar injection every day D-galactose 0.12mg/g, January continuously
[1]Divide some groups after the mice moulding as required again.Mice does following grouping at random during experiment: (1) blank group (not moulding of animal), irritate stomach N.S.(2) moulding matched group (animal-shaped) is irritated stomach N.S.(3) positive drug control group, animal-shaped, filling stomach brain recovering capsule solution (0.5g/kg is clinical two times of adult's dosage).(4)-(6) group is the basic, normal, high dosage group of FYH, irritates the FYH solution (dosage is respectively clinical 2,5 and 10 times adult's dosage) of stomach 5%, 10% and 20% respectively.Each is organized the mouse stomach volume and is 10ml/kg, once a day, and continuous two weeks.After the last administration, make following index determining.
1.2.1FYH the influence that the learning and memory of aging model mice is kept
1.2.1.1 step down test is imitated literature method
[2], earlier mice was put into diving tower reaction chamber endoadaptation environment 3 minutes, pass to the 36V alternating current to the copper grid at the bottom of the reaction chamber then, after animal is shocked by electricity, tend to skip to platform, to keep away noxious stimulation.Because platform is narrow, inconvenience stops, and forces it to skip to the copper grid once more or repeatedly, but rebound platform promptly again after being shocked by electricity so trained 5 minutes, writes down the number of times that every Mus is shocked by electricity, with this school grade as this Mus.Recast test after 24 hours.During test, earlier mice is placed on the platform, time (incubation period) and the 3 minutes endogenous cause of ill that the record mice jumps off platform is for the first time jumped off platform and the number of times (being errors number) that shocked by electricity, with this index of keeping as memory.The results are shown in Table 1.
Table 1 FLQ is to influence (diving tower method) x ± SD of aging model learning and memory of little mouse, n=20
Annotate: compare with the moulding matched group:
*: P＜0.05
*: P＜0.01.
Compare with the blank group:
△: P＜0.05;
△ △: P＜0.01
Above result shows, FYH significant prolongation mice diving tower incubation period, obviously reduces the errors number (P＜0.01) of diving tower simultaneously.
1.2.1.2 it is a collection of that square type maze test is got the qualified mice of moulding, divides into groups and administration (or N.S) by above-mentioned test.Be administered to the 11st day, fasting was got the food training as the labyrinth after 12 hours.Mice is put into the starting area, arrives the target area through the rectangle labyrinth.Go to the wrong way in the way, help its correction.Reach its feed of target area relief 5 minutes.So practise 10 times every day, continuous three days.The 4th day (being the fortnight of administration) formal experiment.Each group is chosen 20 of the consistent mices of motility, and the record mice arrives the time of target area and the number of times of going to the wrong way midway from the starting area
[3]Doing the merging of twice, two secondary data continuously averages as the school grade of mice.Animal continues administration, repeats above-mentioned test after the week, and what the gained data were promptly represented to remember keeps, and the results are shown in Table 2:
Table 2 FYH is to improvement effect (maze method) x ± SD n=20 of aging model learning and memory of little mouse
Annotate: compare with the moulding matched group:
*: P＜0.05
*: P＜0.01.
Compare with the blank group:
△: P＜0.05;
△ △: P＜0.01
Above result shows that FYH obviously improves the school grade that the aging model mice walks the labyrinth, reduces the memory phase of keeping and walks the errors number that the labyrinth takes place, and promptly strengthens the maintenance effect of mice to memory.
1.2.2FYH influence to monoamine neurotransmitters in aging model mice serum MDA and SOD content and the cerebral tissue
It is a collection of to get mice, grouping and dosage and method are tested with above-mentioned 1.2.1. but administration (or N.S) time be two courses of treatment (28 days), after the last administration, got blood and got the full brain of mice from femoral artery in one hour. measure the content of respectively organizing malonaldehyde the mice serum (MDA) and superoxide dismutase (SOD) respectively by the described method of testing cassete that Nanjing is built up bio-engineering research and provided
[4]Measure the content of monoamine neurotransmitter in the mouse brain tissue with fluorescence spectrophotometry.Operational approach and result are as follows:
The assay of serum malonaldehyde (MDA), the according to the form below operation
| Standard pipe | The blank pipe of standard | Measure pipe | Measure blank pipe | |
| 10nmol/m standard substance (ml) | 0.1 | |||
| Dehydrated alcohol (ml) | 0.1 | |||
| Specimen (ml) | 0.1 | 0.1 | ||
| Reagent one (ml) | 0.1 | 0.1 | 0.1 | 0.1 |
Mixing (shaking several test tube racks down)
| Reagent two (ml) | 3 | 3 | 3 | 3 |
| Reagent three (ml) | 1 | 1 | 1 | |
| 50% glacial acetic acid (ml) | 1 |
Vortex vortex mixer mixing, the test tube mouth is tightened with antistaling film, sting an aperture,, take out back flowing water cooling in 95 ℃ of water-baths 40 minutes, centrifugal then (4000rpm) 10 minutes, get supernatant, the 1cm of 532nm place optical path, distilled water zeroing colorimetric, survey and respectively manage the absorbance value, press the content of MDA in the column count serum again:
The vitality test of serum superoxide dismutases (SOD), the according to the form below operation
| Reagent | Measure pipe | Control tube |
| No. 1 reagent (ml) | 1.00 | 1.0 |
| Sample (ml) | 0.03 | |
| Distilled water (ml) | 0.50 | 0.5+0.03 |
| No. 2 reagent (ml) | 0.1 | 0.1 |
| No. 3 reagent (ml) | 0.1 | 0.1 |
| Reagent | Measure pipe | Control tube |
| No. 4 reagent (ml) | 0.1 | 0.1 |
With the abundant mixing of vortex vortex mixer, put 37 ℃ of waters bath with thermostatic control 40 minutes
| Developer (ml) | 2 | 2 |
Mixing is poured into after 10 minutes in the 1cm optical path cuvette, and the distilled water zeroing in wavelength 550nm place colorimetric, is calculated as follows SOD vigor (nu/ml)
The results are shown in Table 3:
Table 3 FYH is to the x ± SD that influences of mice plasma MDA and SOD
Annotate: compare with the moulding matched group:
*: P＜0.05
*: P＜0.01.
Compare with the blank group:
△: P＜0.05;
△ △: P＜0.01
Above result shows that FYH can obviously reduce the activity of blood plasma lipide peroxidating content of mda and raising blood plasma superoxide dismutase (SOD).
Three, improve the skin aging symptom
Have 45～56 years old women volunteer 45 example that skin is easily dry, canthus wrinkle, senile plaque, winter skin pruritus occurs, oral product of the present invention (the white soft capsules of embodiment 3 gained), in in October, 2005 to 2005 year December, after continuous 2 months, through paying a return visit the experimenter, the result is as follows in the statistics back:
The result shows that pharmaceutical composition of the present invention has tangible effect to beautifying skin, can comparatively fast increase the moisture and the elasticity of skin, improves the skin physical appearance.The mental status of observing user simultaneously obviously improves.
Claims (8)
1. pharmaceutical composition that is used to prevent and treat the female aging disease is characterized in that each functional component proportion of composing is in the prescription:
Soybean isoflavone or Radix Puerariae isoflavone class plant isoflavone 1.5%～30%
Panoxadiol's type saponin 1.5%～22.1%
Containing the 2%-20% triterpene saponin is the Rhizoma Cimicifugae extract 1.2%～17.9% of main active
The trienic acid 30%～95.8% that contains 18 carbon atoms.
2. the pharmaceutical composition that is used to prevent and treat the female aging disease according to claim 1 is characterized in that; Panoxadiol's type saponin is the diol type dammarane type saponin that is derived from panax species, and the trienic acid that contains 18 carbon atoms is gamma-Linolenic acid, alpha-linolenic acid and Pinolenic acid.
3. preparation method that is used to prevent and treat the drug combination preparation of female aging disease is characterized in that: contain soybean isoflavone or Radix Puerariae isoflavone class plant isoflavone 5～100mg, panoxadiol's type saponin 5～74mg in the dosage that the finished product of making uses at every turn, contain the 2%-20% triterpene saponin as the Rhizoma Cimicifugae extract 4～60mg of main active, contain the trienic acid 100～321mg of 18 carbon atoms.
4. the preparation method that is used to prevent and treat the drug combination preparation of female aging disease according to claim 3 is characterized in that: used solvent substrate is one or more compositions in monounsaturated fatty acid or polyunsaturated fatty acid plant edible food or the medicinal oil during preparation.
5. the preparation method that is used to prevent and treat the drug combination preparation of female aging disease according to claim 3 is characterized in that: used solvent substrate is an oleic acid during preparation.
6. the preparation method that is used to prevent and treat the drug combination preparation of female aging disease according to claim 3 is characterized in that: used solvent substrate is a linoleic acid during preparation.
7. the preparation method that is used to prevent and treat the drug combination preparation of female aging disease according to claim 3 is characterized in that: add the deodorant tune Oleum Cinnamomi in the medicinal liquid.
8. the preparation method that is used to prevent and treat the drug combination preparation of female aging disease according to claim 3 is characterized in that: make acceptable soft capsule, liquid capsule or liquid agent preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610011056A CN1899389B (en) | 2006-07-18 | 2006-07-18 | Medicinal composition for preventing and treating female senile diseases and method for preparing said preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610011056A CN1899389B (en) | 2006-07-18 | 2006-07-18 | Medicinal composition for preventing and treating female senile diseases and method for preparing said preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1899389A CN1899389A (en) | 2007-01-24 |
| CN1899389B true CN1899389B (en) | 2010-05-12 |
Family
ID=37655499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200610011056A Active CN1899389B (en) | 2006-07-18 | 2006-07-18 | Medicinal composition for preventing and treating female senile diseases and method for preparing said preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1899389B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1475269A (en) * | 2003-07-31 | 2004-02-18 | 凯 曹 | Rhizoma cimicifugae extract and its preparation method |
| CN1657073A (en) * | 2004-02-16 | 2005-08-24 | 邱芳龙 | Health-care product for preventing woman climacteric syndrom and improving youth activity |
-
2006
- 2006-07-18 CN CN200610011056A patent/CN1899389B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1475269A (en) * | 2003-07-31 | 2004-02-18 | 凯 曹 | Rhizoma cimicifugae extract and its preparation method |
| CN1657073A (en) * | 2004-02-16 | 2005-08-24 | 邱芳龙 | Health-care product for preventing woman climacteric syndrom and improving youth activity |
Non-Patent Citations (4)
| Title |
|---|
| 张晓晓等.具有雌激素类似作用的中药研究进展.中西医结合学报3 2.2005,3(2),149-153. |
| 张晓晓等.具有雌激素类似作用的中药研究进展.中西医结合学报3 2.2005,3(2),149-153. * |
| 赵卫杰等.中药及其活性成分防治骨质疏松症的药理研究.时珍国医国药16 1.2005,16(1),68-70. |
| 赵卫杰等.中药及其活性成分防治骨质疏松症的药理研究.时珍国医国药16 1.2005,16(1),68-70. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1899389A (en) | 2007-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101249633B1 (en) | Use of ginkgo complexes for the enhancement of cognitive functions and the alleviation of mental fatigue | |
| Vilas-Boas et al. | Cholestatic liver injury induced by food additives, dietary supplements and parenteral nutrition | |
| CN105079009B (en) | Prevention and/or the composition for the treatment of cardiovascular and cerebrovascular disease | |
| EP1878445A1 (en) | A method, formulation and use thereor with improved oral absorption of drugs or nutrients | |
| Prasad et al. | The preliminary phytochemical analysis and oral acute toxicity study of stem bark of Syzygium cumini | |
| CN105394749A (en) | Formula, preparation method and application of astaxanthin-containing health food | |
| Arooj et al. | A comprehensive review of the bioactive components of sesame seeds and their impact on bone health issues in postmenopausal women | |
| López-Rios et al. | Toxicological assessment of Xanthigen® nutraceutical extract combination: Mutagenicity, genotoxicity and oral toxicity | |
| AU2006347122B2 (en) | Antiobesity composition containing component originating in the bark of tree belonging to the genus Acacia | |
| CN105616557A (en) | Self-emulsifying soft capsule with peony seed oil and application of self-emulsifying soft capsule to preparing blood fat reducing healthcare products or medicines | |
| US3993756A (en) | Antilipemic agent containing a soybean oil fraction | |
| CN100467040C (en) | Medicine composition for improving cognitive function of senile organism | |
| CN101234160A (en) | Fat-reducing and liver-protecting Chinese medicine preparation and preparation thereof | |
| Sindhu et al. | Phytosterols: Physiological functions and therapeutic applications | |
| CN1899389B (en) | Medicinal composition for preventing and treating female senile diseases and method for preparing said preparation | |
| CN101229233B (en) | Chinese traditional medicine preparation for antiatheroscloresis and liver-protection, and preparingng method thereof | |
| CN100402052C (en) | Blood fat-reducing medicine and its preparation method | |
| CN102106534A (en) | Composition for assisting in lowering blood fat and preparation method thereof | |
| CN105560308B (en) | Flower of JINHUAKUI is preparing the application in the product for preventing and treating prostatic disorders | |
| CN102802653B (en) | Decolorized extracts of the plant pandanus conoideus | |
| CN107183716A (en) | A kind of liver protection is dispelled wine health-care food composition and preparation method thereof | |
| RU2707300C2 (en) | Method of producing drug having thyrotropic and antioxidant activity | |
| JP2004067526A (en) | Composition effective for prevention/alleviation of symptom of atopic disease | |
| CN109699887A (en) | A kind of peony seed oil blood fat reducing soft capsule and preparation method thereof | |
| Mustari et al. | Growth performance, hematological parameters and lipid profile of mice treated with black seed oil and vitamin-E |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: YUXI WINHEY WEISHENGTANG HEALTH FOOD CO., LTD. Free format text: FORMER OWNER: XIANGGEXIMA BIO-TECHNOLOGY CO., LTD., KUNMING CITY Effective date: 20111111 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 650106 KUNMING, YUNNAN PROVINCE TO: 653100 YUXI, YUNNAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20111111 Address after: 653100 No. 5, Chuangxin Road, hi tech Development Zone, Yunnan, Yuxi Patentee after: Yuxi Winhey Weishengtang Health Food Co., Ltd. Address before: 650106, 9 North Road, hi tech North Zone, Yunnan, Kunming Province, Yunnan University Science Park two A2-406 Patentee before: Xianggexima Biological Technology Co., Ltd., Kunming |